Top

Drugs

Published in:

01-02-2008 | Adis Drug Profile

Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted Adsorbed) [Cervarix™]

Authors: Susan J. Keam, Diane M. Harper

Published in: Drugs | Issue 3/2008

Abstract

▴ Cervarix™ is a prophylactic vaccine comprised of a mixture of virus-like particles derived from the L1 capsid proteins of human papillomavirus (HPV) types 16 and 18 formulated with the AS04 adjuvant system. It is administered by intramuscular injection as a three-dose vaccine regimen at 0, 1 and 6 months. The vaccine is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN 2 and CIN 3) and cervical cancer causally related to HPV types 16 and 18.
▴ In randomized, double-blind, phase II or III trials in >19 000 women aged 15–25 years, the HPV 16/18 vaccine showed high efficacy in preventing CIN 2+ associated with HPV 16/18. Cross-protection against new incident or 6-month persistent HPV 45 or HPV 31 infection was also evident. Phase II follow-up was for at least 5.5 years, and the phase III interim analysis was at ≈15 months after the first vaccine dose.
▴ In a bridging study, in adolescent girls aged 10–14 years, the HPV 16/18 vaccine induced twice the already high antibody titres as it did in young women (aged 15–25 years). The immune response in older women (aged 26–55 years) at 24 months in another study was ≥8-fold higher than antibody levels reported in younger age groups. Anti-HPV 16/18 antibody responses were greater with an AS04-adjuvanted HPV 16/18 vaccine than with an aluminium salt-adjuvanted formulation.
▴ The HPV 16/18 vaccine was generally well tolerated and injection-site reactions were the most common vaccine-related adverse events reported.

The use of trade names is for product identification purposes only and does not imply endorsement.

Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 version 2.0. Lyon: IARC Press, 2004

Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006 Aug 21; 24 Suppl. 3: S11–25CrossRef

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar 30; 55(2): 74–108PubMedCrossRef

Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007 Jan 28; 57(1): 7–28PubMedCrossRef

Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007 Sep 8; 370(9590): 890–907PubMedCrossRef

Davy MLJ, Dodd TJ, Luke CG, et al. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003 Jan; 101(1): 38–45PubMedCrossRef

National Cervical Screening Program. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra (ACT): National Cervical Screening Program, 2005 Jun 9

Chhieng DC, Gallaspy S, Yang H, et al. Women with atypical glandular cells: a long-term follow-up study in a high-risk population. Am J Clin Pathol 2004 Oct; 122(4): 575–9PubMedCrossRef

Williamson A-L, Passmore J-A, Rybicki EP. Strategies for the prevention of cervical cancer by human papillomavirus vaccination. Best Pract Res Clin Obstet Gynaecol 2005 Aug; 19(4): 531–44PubMedCrossRef

10.

Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005 May; 14(5): 1157–64PubMedCrossRef

11.

Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004 Aug 20; 111(2): 278–85PubMedCrossRef

12.

Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005 Sep 17; 366(9490): 991–8PubMedCrossRef

13.

Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005 Mar; 32 Suppl. 1: S16–24PubMedCrossRef

14.

Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007 Feb 28; 297(8): 813–9PubMedCrossRef

15.

Burchell AN, Winer RL, de Sanjosé S, et al. Chapter 6: epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006 Aug 21; 24 Suppl. 3: S52–61CrossRef

16.

Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005 Jun 1; 191(11): 1808–16PubMedCrossRef

17.

Grainge MJ, Seth R, Guo L, et al. Cervical human papillomavirus screening among older women. Emerg Infect Dis 2005 Nov; 11(11): 1680–5PubMedCrossRef

18.

Kahn MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97(14): 1072–9CrossRef

19.

Frazer IH, Cox JT, Mayeaux Jr EJ, et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. Pediatr Infect Dis J 2006 Feb; 25 (2 Suppl.): S65–81PubMedCrossRef

20.

Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005 Mar 18; 23(17-18): 2388–94PubMedCrossRef

21.

Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007; 111(3): 145–53PubMedCrossRef

22.

Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003 Jul 7; 89(1): 101–5PubMedCrossRef

23.

Muñoz N, Castellsagué X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006 Aug 21; 24 Suppl. 3: S1–10CrossRef

24.

Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005 Apr; 6(4): 204PubMedCrossRef

25.

Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007; 38(3): 189–97PubMedCrossRef

26.

Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003 Jan 13; 88(1): 63–73PubMedCrossRef

27.

Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004 Sep; 16(5): 485–91PubMedCrossRef

28.

Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003 Oct 10; 106(6): 896–904PubMedCrossRef

29.

French KM, Barnabas RV, Lehtinen M, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007 Feb 12; 96(3): 514–8PubMedCrossRef

30.

Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007 Jan 15; 96(1): 143–50PubMedCrossRef

31.

Juday TR, Kruzikas DT, Taylor DCA, et al. Clinical benefits associated with vaccination against human papillomavirus: the contribution of cross-protection [abstract no. O-1472]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27–30; San Francisco (CA)

32.

Siebert U, Schwarz TF, Rogoza R, et al. Impact of the age of vaccination against cervical cancer on long-term public health and economic effects in Germany: results from a Markov model [abstract]. 6th World Congress of the International Health Economics Association; 2007 Jul 5–11; Copenhagen

33.

Boot HJ, Wallenburg I, de Melker HE, et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 2007 Aug 14; 25(33): 6245–56PubMedCrossRef

34.

Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007 Jul 20; 25(29): 5399–408PubMedCrossRef

35.

Newall AT, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007 Apr; 7(4): 289–96PubMedCrossRef

36.

Goldie SJ, Kim JJ, Kobus K, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007 Aug 14; 25(33): 6257–70PubMedCrossRef

37.

Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines — underlying mechanisms. Vaccine 2006 Aug 21; 24 Suppl. 3: S106–13CrossRef

38.

Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006 Aug 14; 24(33-34): 5937–49PubMedCrossRef

39.

Stanley M. Immune responses to human papillomavirus. Vaccine 2006 Mar 30; 24 Suppl. 1: S16–22PubMedCrossRef

40.

Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004 Feb; 13(2): 324–7PubMedCrossRef

41.

Stanley M. Prophylactic HPV vaccines. J Clin Pathol 2007 Sep; 60(9): 961–5PubMedCrossRef

42.

Garçon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminium salt. In: Schijns VEJC, O’Hagan DT, editors. Immunopotentiators in modern vaccines. London: Elsevier Academic Press, 2006: 161–77CrossRef

43.

Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine 2007 May 10; 25(19): 3752–62PubMedCrossRef

44.

GlaxoSmithKline Biologicals s.a. Rixensart Belgium. Summary of product characteristics. Fendrix suspension for injection. Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed) [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Nov 5]

45.

GlaxoSmithKline Biologicals s.a. Rixensart, Belgium. Summary of product characteristics. Cervarix suspension for injection. Human papillomavirus vaccine [types 16,18] (recombinant, adjuvanted, adsorbed) [online]. Available from URL: http://www.emea.europa.eu/ [Accessed 2007 Oct 4]

46.

GlaxoSmithKline Biologicals s.a. Rixensart Belgium. Scientific discussion. Cervarix suspension for injection. Human papillomavirus vaccine [types 16,18] (recombinant, adjuvanted, adsorbed) [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Oct 4]

47.

Siddiqui MAA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®). Drugs 2006; 66(9): 1263–71PubMedCrossRef

48.

Sanofi Pasteur MSD. Summary of product characteristics. Gardasil, suspension for injection. Human papillomavirus vaccine [Types 6, 11, 16, 18] (recombinant, adsorbed). [online]. Available from URL: http://www.emea.europa.eu [Accessed 2007 Sep 29]

49.

Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003; 71(5): 2498–507PubMedCrossRef

50.

De Becker G, Moulin V, Pajak B, et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000 Jun; 12(6): 807–15PubMedCrossRef

51.

Ismaili J, Rennesson J, Aksoy E, et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 2002 Jan 15; 168(2): 926–32PubMed

52.

Boland G, Beran J, Lievens M, et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004 Dec 2; 23(3): 316–20PubMedCrossRef

53.

Thoelen S, De Clercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001 Mar 21; 19(17-19): 2400–3PubMedCrossRef

54.

Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005 Nov; 68(5): 2298–303PubMedCrossRef

55.

Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007 Jun; 40(6): 564–71PubMedCrossRef

56.

Schwarz TF. An AS04-containing human papillomavirus 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15–55 years old [abstract no. 1008]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 50s

57.

Schwarz TF, Dubin G. Human papillomavirus (HPV) 16/18 L1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women aged up to 55 years [abstract no. 3007]. J Clin Oncol 2007; 25 (18 Suppl. Pt 1): 119s

58.

Schwarz T, Descamps D. Immune response in women up to 55 years of age vaccinated with Cervarix™, the HPV-16/18 L1 VLP AS04 vaccine candidate. The HPV Vaccine Study Group for Adult Women. 15th European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2007 Oct 4–6; Monte Carlo

59.

Poncelet S, Cambron P, Giannini SL, et al. Induction of cervical mucosal HPV IgG in women 15–55 years old following systemic vaccination with GSKs prophylactic cervical cancer candidate vaccine. The HPV Vaccine Study Group for Adult Women [abstract no. PS19–25]. 24th International Papillomavirus Conference; 2007 Nov 3–9; Beijing

60.

Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004 Nov 13; 364(9447): 1757–65PubMedCrossRef

61.

Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006 Apr 15; 367(9518): 1247–55PubMedCrossRef

62.

Gall SA, Teixeira J, Wheeler CM, et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine [abstract no. 4900]. American Association for Cancer Research Annual Meeting Proceedings; 2007 Apr 14–18; Los Angeles (CA)

63.

Harper DM, Dubin G. Sustained HPV-16 and 18 antibody levels through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine [abstract]. The HPV vaccine Study Group. 15th International Meeting of the European Society for Gynaecological Oncology (ESGO); 2007 Oct 28–Nov 1; Berlin [online]. Available from URL: http://www.multiwebcast.com/esgo/2007/15th/ [Accessed 2007 Dec 8]

64.

Dessy F, David MP, Schuind A, et al. Evaluation of HPV neutralizing antibodies from an extended follow up study through 5.5 years in women vaccinated with GSKs prophylactic cervical cancer candidate vaccine. The HPV Vaccine study group [abstract no. 5B-01]. 24th International Papillomavirus Conference; 2007 Nov 3–9; Beijing

65.

David M-P, Hardt K, Tibaldi F, et al. Long-term persistence of detectable anti-HPV-16 and anti-HPV-18 antibodies induced by Cervarix™: modelling of sustained antibody responses [abstract no. PS26-37]. 24th International Papillomavirus Conference; 2007 Nov 3–9; Beijing

66.

Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 Jun 30; 369(9580): 2161–70PubMedCrossRef

67.

Paavonen J, Jenkins D, Bosch FX, et al. Multiple oncogenic HPV infection and the development of incident CIN2+ lesions in a phase III trial of a HPV-16/18 L1 VLP vaccine adjuvanted with AS04 in a broad population of women. The HPV PATRICIA study group [abstract no. PA1-03]. 24th International Papillomavirus Conference; 2007 Nov 3–9; Beijing

68.

Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007 May 22; 25(21): 4324–33PubMedCrossRef

69.

Trottier H, Mahmud S, Lindsay L, et al. Risk of cervical lesions following incident human papillomavirus infection in young women without evidence of prior exposure [abstract no. 7B-10]. 24th International Papillomavirus Conference; 2007 Nov 3–9; Beijing

70.

Cruickshank M, Teixeira J, Gall S, et al. Efficacy and safety of GSK’s HPV vaccine in women initially seropositive or seronegative for HPV-16/18 in a phase III trial [abstract no. SS1-2]. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2007 Oct 4–6; Monte Carlo

71.

Skinner R, Verheijen R, Martens M, et al. Estimating prior HPV-16/18 exposure by age group of women enrolled in phase III clinical trials of GSK’s HPV vaccine [abstract no. SS1-2]. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2007 Oct 4–6; Monte Carlo

72.

Harper DM. HPV vaccines: lessons from clinical trials. The HPV-16/18 VLP vaccine adjuvanted with AS04 [abstract no. TC2-4]. 15th European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2007 Oct 4–6; Monte Carlo

73.

Szarewski A, Lazcano E, Angsuwathana S, et al. Safety of uman papillomavirus (HPV) 16/18 AS04 cervical cancer vaccine candidate in women aged 26 years or older. The HPV VIVIANE study group [abstract no. SS2-4]. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2007 Oct 4–6; Monte Carlo

74.

GlaxoSmithKline. GSK submits Cervarix™ licence application to Japan’s health authorities [media release]. 2007 Sep 28

75.

Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007 Aug 15; 298(7): 743–53PubMedCrossRef

76.

ClinicalTrials.gov. Immunogenicity of GSK Bio’s HPV vaccine (580299) versus Merck’s Gardasil® in healthy females 18–45 years of age [online]. Available from URL: http://www.climcaltrials.gov [Accessed 2007 Oct 4]

77.

ClinicalTrials.gov. Human papillomavirus (HPV) vaccine efficacy, immunogenicity and safety trial in adult Japanese women with GSK Biologicals HPV-16/18 vaccine [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2007 Oct 4]

78.

ClinicalTrials.gov. Study to evaluate the efficacy of the human papillomavirus vaccine in healthy adult women of 26 years of age and older [online]. Available from URL: http://www.dinicaltrials.gov [Accessed 2007 Oct 24]

79.

Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006 Aug; 17(8): 517–21PubMedCrossRef

80.

Paavonen J. Clinical issues of prophylactic HPV vaccination: post marketing surveillance [abstract no. PS1-1-2]. European Research Organisation on Genital Infection and Neoplasia (EUROGIN); 2007 Oct 4–6; Monte Carlo

81.

Lehtinen M, Herrero R, Mayaud P, et al. Chapter 28: studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006 Aug 21; 24 Suppl. 3: S233–41CrossRef

Title: Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted Adsorbed) [Cervarix™]
Authors: Susan J. Keam
Diane M. Harper
Publication date: 01-02-2008
Publisher: Springer International Publishing
Published in: Drugs / Issue 3/2008
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868030-00007

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted Adsorbed) [Cervarix™]

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Current and Future Therapeutic Options in the Management of Invasive Aspergillosis

Adult-Onset Still’s Disease

Sildenafil

Drugs for Cardiovascular Disease Prevention in Women

Amlodipine/Valsartan

Locally Advanced and Metastatic Gastric Cancer